Brown AM - Search Results

1

Multi-parameter in vitro toxicity testing of crizotinib, sunitinib, erlotinib, and nilotinib in human cardiomyocytes.

Doherty KR, Wappel RL, Talbert DR, Trusk PB, Moran DM, Kramer JW, Brown AM, Shell SA, Bacus S. Doherty KR, et al. Among authors: brown am. Toxicol Appl Pharmacol. 2013 Oct 1;272(1):245-55. doi: 10.1016/j.taap.2013.04.027. Epub 2013 May 21. Toxicol Appl Pharmacol. 2013. PMID: 23707608

2

MICE models: superior to the HERG model in predicting Torsade de Pointes.

Kramer J, Obejero-Paz CA, Myatt G, Kuryshev YA, Bruening-Wright A, Verducci JS, Brown AM. Kramer J, et al. Among authors: brown am. Sci Rep. 2013;3:2100. doi: 10.1038/srep02100. Sci Rep. 2013. PMID: 23812503 Free PMC article.

3

Quantitative Profiling of the Effects of Vanoxerine on Human Cardiac Ion Channels and its Application to Cardiac Risk.

Obejero-Paz CA, Bruening-Wright A, Kramer J, Hawryluk P, Tatalovic M, Dittrich HC, Brown AM. Obejero-Paz CA, et al. Among authors: brown am. Sci Rep. 2015 Nov 30;5:17623. doi: 10.1038/srep17623. Sci Rep. 2015. PMID: 26616666 Free PMC article.

4

Alfuzosin delays cardiac repolarization by a novel mechanism.

Lacerda AE, Kuryshev YA, Chen Y, Renganathan M, Eng H, Danthi SJ, Kramer JW, Yang T, Brown AM. Lacerda AE, et al. Among authors: brown am. J Pharmacol Exp Ther. 2008 Feb;324(2):427-33. doi: 10.1124/jpet.107.128405. Epub 2007 Nov 6. J Pharmacol Exp Ther. 2008. PMID: 17986649

5

Increased cardiac risk in concomitant methadone and diazepam treatment: pharmacodynamic interactions in cardiac ion channels.

Kuryshev YA, Bruening-Wright A, Brown AM, Kirsch GE. Kuryshev YA, et al. Among authors: brown am. J Cardiovasc Pharmacol. 2010 Oct;56(4):420-30. doi: 10.1097/FJC.0b013e3181f1d21b. J Cardiovasc Pharmacol. 2010. PMID: 20930594

6

Mechanisms of arsenic-induced prolongation of cardiac repolarization.

Ficker E, Kuryshev YA, Dennis AT, Obejero-Paz C, Wang L, Hawryluk P, Wible BA, Brown AM. Ficker E, et al. Among authors: brown am. Mol Pharmacol. 2004 Jul;66(1):33-44. doi: 10.1124/mol.66.1.33. Mol Pharmacol. 2004. PMID: 15213294

7

A history of the role of the hERG channel in cardiac risk assessment.

Rampe D, Brown AM. Rampe D, et al. Among authors: brown am. J Pharmacol Toxicol Methods. 2013 Jul-Aug;68(1):13-22. doi: 10.1016/j.vascn.2013.03.005. Epub 2013 Mar 26. J Pharmacol Toxicol Methods. 2013. PMID: 23538024

8

The action potential and comparative pharmacology of stem cell-derived human cardiomyocytes.

Peng S, Lacerda AE, Kirsch GE, Brown AM, Bruening-Wright A. Peng S, et al. Among authors: brown am. J Pharmacol Toxicol Methods. 2010 May-Jun;61(3):277-86. doi: 10.1016/j.vascn.2010.01.014. Epub 2010 Feb 11. J Pharmacol Toxicol Methods. 2010. PMID: 20153443

9

High throughput functional screening of an ion channel library for drug safety and efficacy.

Brown AM. Brown AM. Eur Biophys J. 2009 Mar;38(3):273-8. doi: 10.1007/s00249-008-0356-2. Epub 2008 Aug 2. Eur Biophys J. 2009. PMID: 18677468 Review.

10

Variability in the measurement of hERG potassium channel inhibition: effects of temperature and stimulus pattern.

Kirsch GE, Trepakova ES, Brimecombe JC, Sidach SS, Erickson HD, Kochan MC, Shyjka LM, Lacerda AE, Brown AM. Kirsch GE, et al. Among authors: brown am. J Pharmacol Toxicol Methods. 2004 Sep-Oct;50(2):93-101. doi: 10.1016/j.vascn.2004.06.003. J Pharmacol Toxicol Methods. 2004. PMID: 15385083

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,274 results

Search Page